Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-4015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis ; volume:7 ; number:1 ; day:17 ; month:12 ; year:2018 ; pages:1-14 ; date:12.2018
Israel Journal of Health Policy Research ; 7, Heft 1 (17.12.2018), 1-14, 12.2018
- Classification
-
Medizin, Gesundheit
- Creator
-
Ginsberg, Gary M.
Somekh, Eli
Schlesinger, Yechiel
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13584-018-0258-4
- URN
-
urn:nbn:de:101:1-2019030513275505164385
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:04 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ginsberg, Gary M.
- Somekh, Eli
- Schlesinger, Yechiel
- SpringerLink (Online service)
Other Objects (12)
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
Should Colorectal Cancer Screening in Portugal Start at the Age of 45 Years? A Cost-Utility Analysis
Cost-utility of tiotropium in patients with severe asthma
Cost-utility analysis of an implant treatment in dentistry
Cost–utility analysis of a palliative care program in Colombia
Economic efficiency and QALY-based cost-utility analysis in health care
Cost-utility analysis of the UPRIGHT intervention promoting resilience in adolescents
A cost-utility analysis of multimodal pain rehabilitation in primary healthcare
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
Should Colorectal Cancer Screening in Portugal Start at the Age of 45 Years? A Cost-Utility Analysis
Cost-utility of tiotropium in patients with severe asthma
Cost-utility analysis of an implant treatment in dentistry
Cost–utility analysis of a palliative care program in Colombia
Economic efficiency and QALY-based cost-utility analysis in health care
Cost-utility analysis of the UPRIGHT intervention promoting resilience in adolescents
A cost-utility analysis of multimodal pain rehabilitation in primary healthcare
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
Should Colorectal Cancer Screening in Portugal Start at the Age of 45 Years? A Cost-Utility Analysis
Cost-utility of tiotropium in patients with severe asthma
Cost-utility analysis of an implant treatment in dentistry
Cost–utility analysis of a palliative care program in Colombia
Economic efficiency and QALY-based cost-utility analysis in health care
Cost-utility analysis of the UPRIGHT intervention promoting resilience in adolescents
A cost-utility analysis of multimodal pain rehabilitation in primary healthcare
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia